These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

112 related articles for article (PubMed ID: 8141106)

  • 1. Oral ondansetron: a useful addition to the supportive care armamentarium?
    Hesketh PJ
    Am J Clin Oncol; 1994 Apr; 17(2):147-9. PubMed ID: 8141106
    [No Abstract]   [Full Text] [Related]  

  • 2. Comparable safety and antiemetic efficacy of a brief (30-second bolus) intravenous granisetron infusion and a standard (15-minute) intravenous ondansetron infusion in breast cancer patients receiving moderately emetogenic chemotherapy.
    Perez EA; Lembersky B; Kaywin P; Kalman L; Yocom K; Friedman C
    Cancer J Sci Am; 1998; 4(1):52-8. PubMed ID: 9467047
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Optimal control by ondansetron of acute and prolonged emesis induced by chemotherapy without cisplatin].
    Harousseau JL
    Bull Cancer; 1996 Jan; 83(1):71-76. PubMed ID: 8672859
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Evaluation of the anti-emetic effectiveness of two drug formulations of Ondansetron in combined chemotherapy for children with malignant tumors].
    Safonova SA; Gershanovich ML; Punanov IuA; Kolygin BA
    Vopr Onkol; 1999; 45(4):424-8. PubMed ID: 10532104
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Single 8 mg dose of oral ondansetron failed to prevent FAC chemotherapy-induced acute nausea and vomiting.
    Bosnjak SM; Neskovic-Konstantinovic ZB; Jovanovic-Micic DJ; Mitrovic LB; Radulovic SS
    J Chemother; 1996 Aug; 8(4):315-8. PubMed ID: 8873840
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The influence of dexamethasone in the decrease of chemotherapy-induced nausea and vomiting.
    Sarcev T; Secen N; Povazan Dj; Sabo A; Popovic J; Bursac D; Kakas M; Zaric B; Milovancev A
    J BUON; 2007; 12(2):245-52. PubMed ID: 17600880
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Novel pharmacologic form of ondansetron (Zofran)--lingual tablets in the prevention of cytostatic chemotherapy-induced loss of appetite, nausea and vomiting].
    Gershanovich ML; Beresneva IA; Makhnova EV
    Vopr Onkol; 2003; 49(4):505-9. PubMed ID: 14569947
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Granisetron (per os) compared with ondansetron (per os) in the prevention of nausea and vomiting induced by mildly emetogenic chemotherapies. Groupe de Recherches en Cancerologie du Nord].
    Huc P; Block S; Carlier D; Darloy F; Bonneterre ME; Bleuse JP; Fournier C; Bonneterre J
    Bull Cancer; 1998 Jun; 85(6):562-8. PubMed ID: 9752283
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Cost-effectiveness analysis of oral ondansetron and prochlorperazine for preventing nausea and vomiting after moderately emetogenic chemotherapy.
    Kwong WJ; Parasuraman TV
    Pharm Pract Manag Q; 1999 Apr; 19(1):28-41. PubMed ID: 10351607
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Parameters that influence the outcome of nausea and emesis in cisplatin based chemotherapy.
    Tsavaris N; Kosmas C; Mylonakis N; Bacoyiannis C; Kalergis G; Vadiaka M; Boulamatsis D; Iakovidis V; Kosmidis P
    Anticancer Res; 2000; 20(6C):4777-83. PubMed ID: 11205218
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Ramosetron versus ondansetron in the prevention of chemotherapy-induced gastrointestinal side effects: A prospective randomized controlled study.
    Shi Y; He X; Yang S; Ai B; Zhang C; Huang D; Dong M; Liu P; Zhou S; Han X
    Chemotherapy; 2007; 53(1):44-50. PubMed ID: 17202811
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Therapeutic potential of Granisetron (Kitryl) for the prevention of nausea and vomiting induced by cytostatic drugs].
    Gershanovich ML; Beresneva IA
    Vopr Onkol; 1998; 44(2):225-8. PubMed ID: 9615833
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Relative efficacy of ondansetron, granisetron, dolasetron and palonosetron in controlling acute nausea and vomiting associated with platinum-based chemotherapy.
    Hamadani M; Awab A; Chaudhary L; Tfayli A
    J Oncol Pharm Pract; 2006 Jun; 12(2):67-8. PubMed ID: 16984743
    [No Abstract]   [Full Text] [Related]  

  • 14. Use of ondansetron in the control of emesis in autologous peripheral blood stem cell transplant (APBSCT) for solid tumours.
    Leong SS; Teo CP; Tao M; Ang PT
    Singapore Med J; 1998 Sep; 39(9):396-8. PubMed ID: 9885717
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Granisetron and ondansetron for chemotherapy-related nausea and vomiting.
    Zeidman A; Ben Dayan D; Ben Zion T; Kaufman O; Cohen AM; Mittelman M
    Haematologia (Budap); 1998; 29(1):25-31. PubMed ID: 9704254
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Clinical usefulness of ondansetron hydrochloride for nausea and vomiting during repeated courses of chemotherapy for malignant lymphoma--impact of prognosis announcement on anti-emetic effect and evaluation of patient perception of chemotherapy-associated adverse events].
    Kodama F; Mohri H; Motomura S; Fukawa H; Tanabe J; Koharasawa H; Kanamori H; Hashimoto Y; Harano H; Sakai R; Tomita N; Fujimaki K; Takemura S; Hattori M
    Gan To Kagaku Ryoho; 2002 Feb; 29(2):273-9. PubMed ID: 11865634
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The antiemetic efficacy of oral ondansetron plus intravenous dexamethasone in patients with gynecologic malignancies receiving carboplatin-based chemotherapy.
    Markman M; Kennedy A; Webster K; Peterson G; Kulp B; Belinson J
    Gynecol Oncol; 2000 Jul; 78(1):43-6. PubMed ID: 10873408
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Health outcomes and cost-effectiveness of aprepitant in outpatients receiving antiemetic prophylaxis for highly emetogenic chemotherapy in Germany.
    Lordick F; Ehlken B; Ihbe-Heffinger A; Berger K; Krobot KJ; Pellissier J; Davies G; Deuson R
    Eur J Cancer; 2007 Jan; 43(2):299-307. PubMed ID: 17134890
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Omission of day 2 of antiemetic medications is a cost saving strategy for improving chemotherapy-induced nausea and vomiting control: results of a randomized phase III trial.
    Lajolo PP; de Camargo B; del Giglio A
    Am J Clin Oncol; 2009 Feb; 32(1):23-6. PubMed ID: 19194119
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Clinical evaluation of ondansetron suppository].
    Kobayashi F; Yamanouchi T; Shimizu T; Sato H; Adachi I; Sakamoto T; Fujimaki M; Horikoshi I
    Gan To Kagaku Ryoho; 1997 Mar; 24(5):625-7. PubMed ID: 9087300
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 6.